期刊
INVESTIGATIONAL NEW DRUGS
卷 40, 期 6, 页码 1322-1332出版社
SPRINGER
DOI: 10.1007/s10637-022-01298-4
关键词
BMP2; TGF-beta; SMAD; CSCs; EMT; TME
资金
- National Natural Science Foundation of China [21777060]
- Horizontal Project of Jiangsu Medical Vocational College [jcyxhxkt2021-01]
- Biology Discipline Team [jdxktd-2019003]
This article comprehensively summarizes the regulatory role and molecular mechanisms of bone morphogenetic protein 2 (BMP2) in tumorigenesis and development. Research has found that BMP2 plays important roles in cancer cell differentiation, proliferation, survival, and apoptosis, and may serve as an effective therapeutic target for cancer and a new marker for assessing treatment efficacy.
Bone morphogenetic protein 2 (BMP2), a pluripotent factor, is a member of the transforming growth factor-beta (TGF-beta) superfamily and is implicated in embryonic development and postnatal homeostasis in tissues and organs. Experimental research in the contexts of physiology and pathology has indicated that BMP2 can induce macrophages to differentiate into osteoclasts and accelerate the osteolytic mechanism, aggravating cancer cell bone metastasis. Emerging studies have stressed the potent regulatory effect of BMP2 in cancer cell differentiation, proliferation, survival, and apoptosis. Complicated signaling networks involving multiple regulatory proteins imply the significant biological functions of BMP2 in cancer. In this review, we comprehensively summarized and discussed the current evidence related to the modulation of BMP2 in tumorigenesis and development, including evidence related to the roles and molecular mechanisms of BMP2 in regulating cancer stem cells (CSCs), epithelial-mesenchymal transition (EMT), cancer angiogenesis and the tumor microenvironment (TME). All these findings suggest that BMP2 may be an effective therapeutic target for cancer and a new marker for assessing treatment efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据